Profile data is unavailable for this security.
About the company
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
- Revenue in USD (TTM)0.00
- Net income in USD-249.31m
- Incorporated1999
- Employees268.00
- LocationRocket Pharmaceuticals Inc350 5th Ave Ste 7530NEW YORK 10118-7501United StatesUSA
- Phone+1 (646) 440-9100
- Fax+1 (781) 676-2155
- Websitehttps://www.rocketpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spyre Therapeutics Inc | 688.00k | -364.23m | 1.77bn | 30.00 | -- | -- | -- | 2,579.72 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Fusion Pharmaceuticals Inc | 2.04m | -104.28m | 1.83bn | 113.00 | -- | 7.55 | -- | 897.30 | -1.42 | -1.42 | 0.0279 | 2.85 | 0.0069 | -- | 45.84 | 18,053.10 | -35.33 | -35.45 | -37.76 | -38.55 | -- | -- | -5,111.57 | -7,206.24 | -- | -- | 0.1704 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.91bn | 167.00 | 30.03 | 3.40 | 18.94 | 4.64 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 1.94bn | 268.00 | -- | 4.38 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Beam Therapeutics Inc | 360.91m | -134.74m | 1.96bn | 436.00 | -- | 2.15 | -- | 5.43 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 1.97bn | 500.00 | -- | 4.90 | -- | 42.56 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Kymera Therapeutics Inc | 79.41m | -154.59m | 1.97bn | 186.00 | -- | 2.77 | -- | 24.81 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
Myriad Genetics, Inc. | 774.20m | -234.60m | 2.06bn | 2.70k | -- | 2.71 | -- | 2.66 | -2.82 | -2.82 | 9.11 | 8.40 | 0.6792 | 10.41 | 6.53 | 286,740.80 | -20.58 | -- | -23.57 | -- | 68.79 | -- | -30.30 | -- | 1.82 | -225.20 | 0.0485 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.06bn | 7.70k | -- | -- | 19.36 | 0.8263 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Intellia Therapeutics Inc | 52.60m | -485.50m | 2.06bn | 526.00 | -- | 1.99 | -- | 39.21 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.06bn | 383.00 | -- | 2.77 | -- | 70.17 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.07bn | 1.76k | 14.59 | 3.07 | 10.30 | 3.06 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
Vera Therapeutics Inc | 0.00 | -94.30m | 2.08bn | 55.00 | -- | 5.85 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RTW Investments LPas of 31 Mar 2024 | 17.69m | 19.54% |
Wellington Management Co. LLPas of 31 Mar 2024 | 9.16m | 10.12% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 5.19m | 5.74% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.78m | 5.28% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.19m | 4.63% |
Westfield Capital Management Co. LPas of 31 Mar 2024 | 3.98m | 4.40% |
Maverick Capital Ltd.as of 31 Mar 2024 | 3.89m | 4.30% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.87m | 3.17% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.57m | 2.84% |
Citadel Advisors LLCas of 31 Mar 2024 | 2.44m | 2.69% |